Lundbeck

Biospace.com | February 15, 2019

Denmark’s H. Lundbeck A/S and Japan’s Otsuka Pharmaceutical announced that their brexpiprazole failed to meet its primary endpoint in two Phase III clinical trials to treat manic episodes in patients with bipolar I disorder. The drug was approved by the U.S. Food and Drug Administration (FDA) in July 2015 for adjunctive therapy to antidepressants in adults with major depressive disorder and for adults with schizophrenia. It was also approved in Europe and Canada in 2018 and 2017, res...

Pharmaphorum Media Limited | February 27, 2019

Denmark’s Lundbeck has signed an agreement with information business Elsevier, that aims to help organize the masses of scientific data it has available, and make drug research more productive and efficient. The companies have created a big data project that creates a comprehensive database of chemistry and bioactivity to help its research into psychiatric and neurological conditions. They said the new deal is based on Elsevier’s Reaxys information service that quickly retrieves lite...

Jazz, Lundbeck and Alexion | April 05, 2019

The federal government’s probe into pharma’s co-pay assistance charities has snared some of the biggest names in the business, and Thursday the Department of Justice said three drugmakers have inked settlements totaling $122.6 million. Jazz, Lundbeck and Alexion each struck deals with the DOJ—worth $57 million, $52.6 million and $13 million, respectively—to resolve allegations of using payments to charities as “conduits” to help Medicare and other patients aff...

Pharmaceutical Technology | September 20, 2019

Takeda has announced that its drug Trintellix (vortioxetine) has been approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of depression and depressed state. Danish company Lundbeck discovered Trintellix, but since 2017 Lundbeck and Takeda have been collaborating on the development of the drug in Japan. The two companies extended the agreement in 2018 to include co-commercialisation of the drug in Japan following its approval. This approval was based upon a randomise...